Table 1 Univariate and multivariate analysis of NSD paralog expression and clinical variables and their association with overall survival in the HPV+ HNSCC cohort
| Â | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|
Variables | HR (95% CI) | P value | HR (95% CI) | P value | |
Sex | Male vs Female | 0.81 (0.18–3.62) | 0.78 |  |  |
Age | <  60 vs ≥ 60 | 0.96 (0.32–2.83) | 0.94 | 0.13 (0.023–0.70) | 0.02 |
Subsite | Oral Cavity vs Oropharynx | 2.82 (1.02–7.80) | 0.045 | 2.51 (0.55–11.48) | 0.23 |
Other vs Oropharynx | 1.54e-08 (0 - Inf) | 1.00 | 3.72e-10 (0 - Inf) | 1.00 | |
Oral Cavity vs Other | 1.84e08 (0 – Inf) | 1.00 | 6.75e09 (0 - Inf) | 1.00 | |
T Stage | T3 - T4 vs T1 - T2 | 1.03 (0.36–2.91) | 0.96 |  |  |
N Stage | N2b - N3 vs N0 - N2a | 0.41 (0.14–1.19) | 0.10 | 0.19 (0.034–1.047) | 0.06 |
Overall Stage | IV vs I - III | 0.76 (0.26–2.24) | 0.62 | 0.034 (0.004–0.33) | 0.003 |
HPV Type | Other vs 16 | 3.33 (1.14–9.78) | 0.028 | 13.03 (2.46–69.13) | 0.003 |
Smoking History | Heavy Smoker vs Non Smoker | 1.57 (0.47–5.22) | 0.47 |  |  |
NSD1 | Low vs High Expression | 6.15 (1.43–26.32) | 0.015 | 32.88 (3.23–333.33) | 0.003 |
Low vs Mid Expression | 5.95 (1.49–23.81) | 0.012 | 4.94 (0.84–29.41) | 0.08 | |
High vs Mid Expression | 0.97 (0.24–3.91) | 0.96 | 0.15 (0.018–1.23) | 0.08 | |
NSD2 | Low vs High Expression | 5.08 (1.08–23.88) | 0.04 |  |  |
Low vs Mid Expression | 2.93 (0.89–9.67) | 0.08 |  |  | |
High vs Mid Expression | 0.58 (0.10–3.29) | 0.54 |  |  | |
NSD3 | Low vs High Expression | 10.03 (1.98–50.94) | 0.005 | 103.1 (8.55–1.24e03) | 0.0003 |
Low vs Mid Expression | 10.63 (2.03–55.62) | 0.005 | 135.3 (6.62–2.76e03) | 0.001 | |
High vs Mid Expression | 1.06 (0.17–6.63) | 0.95 | 1.31 (0.12–14.34) | 0.82 | |